Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alex K Bryant

Showing results (61-70 of 78) with videos related to

Pageof 8
Sort By:
JCO Oncology Practice|June 18, 2026
Maintenance Pemetrexed/Pembrolizumab Versus Pembrolizumab in Non-Small Cell Lung Cancer: A Propensity Score-Weighted AnalysisGarth W Strohbehn, Molly C Tokaz, Daniel Sanghoon Shin, et al.
JAMA Internal Medicine|May 7, 2019
Association of Treatment With 5α-Reductase Inhibitors With Time to Diagnosis and Mortality in Prostate CancerReith R Sarkar, J Kellog Parsons, Alex K Bryant, et al.
Cancer Medicine|June 20, 2024
Artificial intelligence to unlock real-world evidence in clinical oncology: A primer on recent advancesAlex K Bryant, Rafael Zamora-Resendiz, Xin Dai, et al.
Cancer Medicine|November 7, 2024
Pan-Cancer Survival Impact of Immune Checkpoint Inhibitors in a National Healthcare SystemSean R Miller, Matthew Schipper, Lars G Fritsche, et al.
The Lancet. Oncology|May 31, 2024
Projected environmental and public health benefits of extended-interval dosing: an analysis of pembrolizumab use in a US national health systemAlex K Bryant, Jacqueline R Lewy, R Daniel Bressler, et al.
American Journal of Clinical Oncology|March 10, 2022
Uptake of Adjuvant Durvalumab After Definitive Concurrent Chemoradiotherapy for Stage III Nonsmall-cell Lung CancerAlex K Bryant, Huiying Yin, Matthew J Schipper, et al.
The Lancet. Oncology|November 17, 2024
Effectiveness and safety of immune checkpoint inhibitors in Black patients versus White patients in a US national health system: a retrospective cohort studySean Miller, Ralph Jiang, Matthew Schipper, et al.
JAMA Network Open|March 20, 2024
Adrenal-Permissive Germline HSD3B1 Allele and Prostate Cancer OutcomesRana R McKay, Tyler J Nelson, Meghana S Pagadala, et al.
Cancer|June 10, 2024
Impact of lung cancer screening on stage migration and mortality among the national Veterans Health Administration population with lung cancerDonna M Edwards, Mina Pirzadeh, Tony Van, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 16, 2025
Impact of PSMA PET Staging on Initial Treatment in Newly Diagnosed Prostate CancerSean R Miller, Dana H Chung, Rachel T Gonzalez, et al.
Pageof 8

Showing results (61-70 of 78) with videos related to

Sort By:
Pageof 8
JCO Oncology Practice|June 18, 2026
Maintenance Pemetrexed/Pembrolizumab Versus Pembrolizumab in Non-Small Cell Lung Cancer: A Propensity Score-Weighted AnalysisGarth W Strohbehn, Molly C Tokaz, Daniel Sanghoon Shin, et al.
JAMA Internal Medicine|May 7, 2019
Association of Treatment With 5α-Reductase Inhibitors With Time to Diagnosis and Mortality in Prostate CancerReith R Sarkar, J Kellog Parsons, Alex K Bryant, et al.
Cancer Medicine|June 20, 2024
Artificial intelligence to unlock real-world evidence in clinical oncology: A primer on recent advancesAlex K Bryant, Rafael Zamora-Resendiz, Xin Dai, et al.
Cancer Medicine|November 7, 2024
Pan-Cancer Survival Impact of Immune Checkpoint Inhibitors in a National Healthcare SystemSean R Miller, Matthew Schipper, Lars G Fritsche, et al.
The Lancet. Oncology|May 31, 2024
Projected environmental and public health benefits of extended-interval dosing: an analysis of pembrolizumab use in a US national health systemAlex K Bryant, Jacqueline R Lewy, R Daniel Bressler, et al.
American Journal of Clinical Oncology|March 10, 2022
Uptake of Adjuvant Durvalumab After Definitive Concurrent Chemoradiotherapy for Stage III Nonsmall-cell Lung CancerAlex K Bryant, Huiying Yin, Matthew J Schipper, et al.
The Lancet. Oncology|November 17, 2024
Effectiveness and safety of immune checkpoint inhibitors in Black patients versus White patients in a US national health system: a retrospective cohort studySean Miller, Ralph Jiang, Matthew Schipper, et al.
JAMA Network Open|March 20, 2024
Adrenal-Permissive Germline HSD3B1 Allele and Prostate Cancer OutcomesRana R McKay, Tyler J Nelson, Meghana S Pagadala, et al.
Cancer|June 10, 2024
Impact of lung cancer screening on stage migration and mortality among the national Veterans Health Administration population with lung cancerDonna M Edwards, Mina Pirzadeh, Tony Van, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 16, 2025
Impact of PSMA PET Staging on Initial Treatment in Newly Diagnosed Prostate CancerSean R Miller, Dana H Chung, Rachel T Gonzalez, et al.
Pageof 8